Business Wire

FL-APPLIED-DATA-CORP

Share
ADC Acquires Pinpoint Software, Continues to Expand Total Store Operations Platform

Applied Data Corporation (ADC), the global market leader for its SaaS-based total store operations platform built for retailers , today announced that it has entered into an agreement to acquire Pinpoint Software, Inc., a provider of software solutions driving operational efficiencies and execution for grocers and other retailers, including the world’s leading expiration date management platform, Date Check Pro® . The acquisition is a highly strategic addition to the ADC portfolio which includes ADC’s fresh item management platform, FreshIQ® , and fulfillment orchestration platform, ShopperKit, and will result in a solution that not only reduces food waste and delivers higher sales, but ultimately goes beyond sustainability to a more regenerative approach for retailers.

For most in the global retail space, food waste is a top concern that impacts the bottom line. As wasted food is the number one item going into landfills and contributing to GHG emissions, it is in everyone’s best interest to tackle this issue head-on. Both ADC and Pinpoint share a combined vision to arm retailers with the tools needed to drive sustainability results through a combination of quantification, analysis, and action.

“ADC’s trajectory as a total store operations platform continues to expand to meet the needs of retailers in today’s evolving market,” said Shamus Hines, CEO of ADC. “Pinpoint helps retailers proactively track inventory expiration dates across the store and work together with shoppers to minimize food waste.” Hines adds further, “As a company, we’re committed to enhancing all store operations for food retailers. With elevated consumer interest in sustainability, retailers are faced with the challenge to reduce food waste while also driving sales, and that is where both ADC and Pinpoint come into play.”

For nearly three decades, ADC has been a trusted provider to over 20,000 grocery and convenience store locations. The company’s SaaS platform of industry-tailored retail solutions already includes fulfillment orchestration, recipe management, made to order, label printing, inventory and waste management, food traceability, production planning, ordering, and temperature monitoring. With the addition of Pinpoint’s Date Check Pro , ADC will be able to offer additional reductions in shrink from expired products while also increasing customer satisfaction.

Andrew Hoeft, Founder and CEO of Pinpoint states, “At Pinpoint, we’ve always believed in driving efficiency and ensuring the freshest shopping experience possible for customers. ADC started in Fresh and has a strong belief in helping retailers reduce waste. Combined with our shared emphasis on user adoption with solutions that are easy to use and learn, joining forces with ADC was a perfect marriage. By blending our teams’ knowledge and solutions, we will continue to push the limits of retail operations technology.”

With this acquisition, work will immediately begin on an integration between the platforms in the coming weeks, the ADC website will be enhanced to show the full scope of the combined company.

About Applied Data Corporation

For more than 30 years, ADC has been a food technology innovator. Our platforms, FreshIQ® and ShopperKit, offer retailers an omnichannel approach to total store operations. FreshIQ allows retailers to effectively plan, prepare, analyze, and deliver the fresh food items shoppers want. The ShopperKit platform enables in-store order fulfillment for retailers to receive, prioritize, and process orders from their online counterparts allowing grocers to offer in-store pickup or delivery services to their online customers. ADC’s products are deployed globally in more than 120 grocery and convenience store chains and more than 20,000 locations. Visit www.applieddatacorp.com to learn more.

About Pinpoint

Pinpoint Software, Inc. is the parent company behind Date Check Pro. Founded in 2011 and based in the rapidly growing tech community and grocery tech hub of Madison, WI, Date Check Pro got its start when its founder Andrew Hoeft set out to solve the problem of expired shrink. Today, we help over a thousand supermarket, retail, and convenience store locations around the world eliminate their losses from dated and expired products and provide better products and experiences for their shoppers.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye